Bridge Realization Estimate
ML model predicts what fraction of the bridge is achievable (accuracy: 60%, n=5,839)
Expected realization: 65% of modeled bridge. Strengths: Net-to-Gross Ratio. Risks: Bed Count. Risk-adjusted uplift: $12.9M (vs $19.7M modeled).
EBITDA Bridge — 7 RCM Levers
Each bar shows the annual EBITDA impact at full run-rate. Revenue levers increase top-line; cost levers reduce operating expense; cash acceleration releases working capital. Calibrated to published research bands (Denial 12%→5% = $8-15M on $400M NPR).
Lever Detail
Each value shows its data source. SELLER = seller data room, DEFAULT = model default, BENCHMARK = P75 peer benchmark.
| Lever | Current | Target | Revenue | Cost | EBITDA | WC | Ramp |
|---|---|---|---|---|---|---|---|
| Cost to Collect | 4.5% DEFAULT | 2.5% BENCHMARK | $0 | $7.5M | $7.5M | $0 | 12mo |
| Denial Rate Reduction | 12.0% DEFAULT | 6.5% BENCHMARK | $7.2M | $206K | $7.4M | $0 | 12mo |
| A/R Days Reduction | 52.00 DEFAULT | 38.00 BENCHMARK | $1.2M | $3.4M | $4.6M | $14.4M | 9mo |
| Clean Claim Rate | 88.0% DEFAULT | 96.0% BENCHMARK | $0 | $240K | $240K | $0 | 6mo |
| Net Collection Rate | 93.5% DEFAULT | 25.0% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
| CDI / Case Mix Index | 135.0% DEFAULT | 142.0% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
Implementation Timing Curve
Linear ramp to full run-rate per lever. Month 0 = close date. Partners should expect 60-70% of total uplift realized by month 12.
| Lever | M0 | M3 | M6 | M9 | M12 | M18 | M24 | M36 |
|---|---|---|---|---|---|---|---|---|
| Cost to Collect | $0 | $1.9M | $3.7M | $5.6M | $7.5M | $7.5M | $7.5M | $7.5M |
| Denial Rate Reduction | $0 | $1.9M | $3.7M | $5.6M | $7.4M | $7.4M | $7.4M | $7.4M |
| A/R Days Reduction | $0 | $1.5M | $3.0M | $4.6M | $4.6M | $4.6M | $4.6M | $4.6M |
| Clean Claim Rate | $0 | $120K | $240K | $240K | $240K | $240K | $240K | $240K |
| Cumulative | $0 | $5.4M | $10.7M | $16.0M | $19.7M | $19.7M | $19.7M | $19.7M |
Returns Sensitivity (IRR / MOIC)
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Green = exceeds 20% IRR hurdle. Amber = 15-20%. Red = below hurdle or loss. RCM uplift of $19.7M is added at exit.
| Entry \ Exit | 9.0x | 10.0x | 11.0x | 11.5x | 12.0x |
|---|---|---|---|---|---|
| 8.0x | 65% / 12.2x | 69% / 13.9x | 73% / 15.6x | 75% / 16.5x | 77% / 17.4x |
| 9.0x | 60% / 10.5x | 64% / 12.0x | 68% / 13.5x | 70% / 14.3x | 72% / 15.1x |
| 10.0x | 56% / 9.1x | 60% / 10.5x | 64% / 11.8x | 66% / 12.5x | 68% / 13.2x |
| 11.0x | 52% / 8.0x | 56% / 9.2x | 60% / 10.5x | 62% / 11.1x | 64% / 11.7x |
| 12.0x | 48% / 7.0x | 52% / 8.2x | 56% / 9.3x | 58% / 9.9x | 60% / 10.5x |
Covenant Headroom (at 10x Entry, 6.5x Max Leverage)
Pro forma EBITDA can decline 33% before the 6.5x covenant trips. RCM uplift reduces leverage from 8.5x to 4.3x, adding 4.1 turns of cushion.
5-Year Value Creation Waterfall
EBITDA trajectory: 3% organic growth + RCM uplift ramp (full run-rate at month 18).
| Base EBITDA | RCM Uplift | Total | Margin | |
|---|---|---|---|---|
| Entry | $20.7M | — | $20.7M | 5.5% |
| Year 1 | $21.3M | +$13.1M | $34.5M | 9.2% |
| Year 2 | $22.0M | +$19.7M | $41.7M | 11.1% |
| Year 3 | $22.6M | +$19.7M | $42.3M | 11.3% |
| Year 4 | $23.3M | +$19.7M | $43.0M | 11.5% |
| Year 5 | $24.0M | +$19.7M | $43.7M | 11.7% |
Achievement Sensitivity
What if we only achieve a fraction of each lever? 50% = conservative, 75% = base management case, 100% = plan, 120% = stretch.
| Lever | 50% | 75% | 100% | 120% |
|---|---|---|---|---|
| Cost to Collect | $3.7M | $5.6M | $7.5M | $9.0M |
| Denial Rate Reductio | $3.7M | $5.6M | $7.4M | $8.9M |
| A/R Days Reduction | $2.3M | $3.4M | $4.6M | $5.5M |
| Clean Claim Rate | $120K | $180K | $240K | $288K |
| Total | $9.9M | $14.8M | $19.7M | $23.7M |
Peer Context — Where This Hospital Sits
Key metrics vs 113 size-matched peers. Low percentile on margin/efficiency metrics = more room for improvement = larger bridge opportunity.
| Metric | Hospital | P25 | P50 | P75 | Percentile |
|---|---|---|---|---|---|
| Op Margin | 5.5% | -7.9% | 4.8% | 14.7% | P52 |
| Net-to-Gross | 14.6% | 12.7% | 18.1% | 25.0% | P32 |
| Occupancy | 52.4% | 57.7% | 68.4% | 77.6% | P16 |
| Rev/Bed | $1.1M | $1.0M | $1.3M | $1.6M | P27 |
| Exp/Bed | $1.0M | $895K | $1.2M | $1.6M | P34 |
Bridge Methodology
Coefficients calibrated to published research bands: denial 12%→5% = $8-15M on $400M NPR. Current metrics estimated from HCRIS public data and ML predictions. Target metrics set at P75 peer benchmarks with 60% gap closure assumption. Revenue levers use NPR × delta × avoidable share. Cost levers use claims volume × cost per reworked claim. Working capital from AR reduction is one-time cash (not included in recurring EBITDA). Returns assume 5.5x leverage, 3% organic growth, 10%/yr debt paydown.